Aureka Biotechnologies

Aureka Biotechnologies (寻明生科) is a Tech-Bio company founded in 2023, focused on generative antibody drug development — its founder and CEO is Dr. Weian Zhao, who has framed the company's thesis as "antibody drugs don't just have to be discovered; they can be designed" . Its core platform, AuraIDE™, pairs an antibody-design agent with a closed-loop wet/dry lab: high-throughput single-cell functional screening, a yeast intracellular directed-evolution platform, and structure-informed autonomous evolution, generating a data flywheel for First-in-Class and Best-in-Class antibody pipelines; within its first two-plus years it had delivered projects for multiple MNCs with orders exceeding $10 million . Funding has moved fast: a tens-of-millions Series A in November 2025 co-led by 5Y Capital and Qiming Venture Partners , a $35 million A+ in April 2026 led by Sequoia China , and a $100 million Series B in August 2026 anchored by Granite Asia — bringing cumulative funding to nearly $200 million, per 5Y Capital's reporting . In its most recent framing, the Series B capital is aimed at training next-generation biological foundation models, shifting the company from "using AI to speed drug discovery" toward "using AI to model life systems" .